Tumor microenvironment changes after treatment with avelumab and immune- stimulating agent combinations in patients with advanced solid tumors

Abstract excerpt

<title>Abstract</title> <p> Background The use of immune checkpoint inhibitors (ICIs) has led to a paradigm change in cancer management. Many patients may have inherent primary resistance to ICIs or develop secondary resistance after initial response. The impact of using novel therapeutic combinations of checkpoint blockade (avelumab) with immune stimulating agonists such as anti- OX40 and/or anti- 4-1BB on the...

Topics

Open a Topic to create a Post that cites this publication.

• Antibodies, Monoclonal, Humanized
• Antineoplastic Agents, Immunological
• Biomarkers, Tumor
• Carcinoma, Non-Small-Cell Lung
• Head and Neck Neoplasms
• Immunotherapy
• Mutation
• Urinary Bladder Neoplasms

Identifiers and source

Literature Corpus work

6379d14b-882d-58e2-bbc5-462b4ff089a2

DOI

10.21203/rs.3.rs-7775526/v1